Aeolus Pharmaceuticals Inc Receives $125,000 Series D Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7f5b0b7a-2b0e-4ed6-950b-c1d978c13ff7&Preview=1
Date 11/4/2008
Company Name Aeolus Pharmaceuticals Inc
Mailing Address 23811 Iverness Place Laguna Niguel, CA 92677
Company Description Aeolous Pharmaceutical is a biopharmaceutical company that is developing a new class of catalytic antioxidant compunds, referred to as manganoporphyrins, for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Over the past decade, Aeolus has synthesizec, developed, and analyzed approximately 200 proprietary catalytic antioxidant compounds, all of which have the same core chemical structure.
Proceeds Purposes The Company expects to use the net proceeds of $120,000 that it raised today from this financing to advance the development of AEOL 10150 and for general administrative expenses and working capital.